Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | TNF | P01375 | 1/20 | 0.36 |
| ▸ | DYRK1A | Q13627 | 7/20 | 0.36 |
| ▸ | DYRK2 | Q92630 | 7/20 | 0.36 |
| ▸ | DYRK1B | Q9Y463 | 6/20 | 0.33 |
| ▸ | CCNA2 | P20248 | 5/20 | 0.33 |
| ▸ | CDK2 | P24941 | 5/20 | 0.33 |
| ▸ | CDK5 | Q00535 | 5/20 | 0.33 |
| ▸ | CDK5R1 | Q15078 | 5/20 | 0.33 |
| ▸ | EGLN2 | Q96KS0 | 5/20 | 0.33 |
| ▸ | DYRK3 | O43781 | 4/20 | 0.33 |
| ▸ | CCNT1 | O60563 | 2/20 | 0.33 |
| ▸ | CDK9 | P50750 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30224716 | 0.83 | EGLN2 (0.32) | KDM4EALDH1A1SMN1; SMN2EGLN2 | |
| SCHEMBL10490611 | 0.69 | DYRK3 (0.37) | KDM4EALDH1A1SMN1; SMN2DYRK1ADYRK2 | |
| SCHEMBL24782856 | 0.69 | FYN (0.41) | EGLN2 | |
| SCHEMBL23034388 | 0.69 | HTT (0.31) | DYRK1AEGLN2 | |
| SCHEMBL10490728 | 0.69 | DYRK1A (0.40) | KDM4EDYRK1ADYRK2DYRK1BCCNA2 | |
| SCHEMBL24783510 | 0.66 | ADRA2A (0.37) | KDM4EALDH1A1SMN1; SMN2EGLN2 | |
| SCHEMBL6618351 | 0.65 | CHRM5 (0.40) | EGLN2 | |
| SCHEMBL11783762 | 0.65 | HTT (0.49) | KDM4EALDH1A1SMN1; SMN2TNFDYRK1A | |
| SCHEMBL6620739 | 0.64 | KDM4E (0.39) | KDM4EALDH1A1SMN1; SMN2TNF | |
| SCHEMBL31553137 | 0.64 | KDM4E (0.39) | KDM4EALDH1A1SMN1; SMN2TNFDYRK1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12110294-B2 | CD73 compounds | GILEAD SCIENCES, INC. (US) | 2024-10-08 | — | — | US | disclosed |
| US-20230039553-A1 | CD73 COMPOUNDS | GILEAD SCIENCES, INC. | 2023-02-09 | — | — | US | disclosed |
| EP-2903978-B1 | GDF-8 INHIBITORS | RIGEL PHARMACEUTICALS INC (US) | 2022-12-07 | — | — | EP | disclosed |
| WO-2021058595-A1 | HERBICIDAL COMPOUNDS | SYNGENTA CROP PROTECTION AG (CH) | 2021-04-01 | — | — | WO | disclosed |
| WO-2021058595-A1 | HERBICIDAL COMPOUNDS | SYNGENTA CROP PROTECTION AG (CH) | 2021-04-01 | — | — | WO | disclosed |
| US-10858335-B2 | 2,3-Disubstituted pyridine compounds as TGF-β inhibitors and methods of use | RIGEL PHARMACEUTICALS, INC. (US) | 2020-12-08 | — | — | US | disclosed |
| US-10858335-B2 | 2,3-Disubstituted pyridine compounds as TGF-β inhibitors and methods of use | RIGEL PHARMACEUTICALS, INC. (US) | 2020-12-08 | — | — | US | disclosed |
| US-20190284155-A1 | 2,3-Disubstituted Pyridine Compounds as TGF-Beta Inhibitors and Methods of Use | RIGEL PHARMACEUTICALS, INC. (US) | 2019-09-19 | — | — | US | disclosed |
| US-20190284155-A1 | 2,3-Disubstituted Pyridine Compounds as TGF-Beta Inhibitors and Methods of Use | RIGEL PHARMACEUTICALS, INC. (US) | 2019-09-19 | — | — | US | disclosed |
| EP-3129367-B1 | 2,3-DISUBSTITUTED PYRIDINE COMPOUNDS AS TGF-BETA INHIBITORS | RIGEL PHARMACEUTICALS INC (US) | 2019-09-04 | — | — | EP | disclosed |
| US-6248740-B1 | FOR SUPPRESSION OF HISTAMINE OR EOSINOPHIL CHEMOTAXIS TO TREAT ASTHMA; ANTIALLERGENIC | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2001-06-19 | — | — | US | disclosed |
| EP-0979231-A1 | CONDENSED PYRIDAZINE DERIVATIVES, THEIR PRODUCTION AND USE | Takeda Chemical Industries, Ltd. (JP) | 2000-02-16 | — | — | EP | disclosed |
| EP-0562439-B1 | Triazolopyridazines as antioasthmatics | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 1999-06-09 | — | — | EP | disclosed |
| WO-1998049167-A1 | CONDENSED PYRIDAZINE DERIVATIVES, THEIR PRODUCTION AND USE | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1998-11-05 | — | — | WO | disclosed |
| US-5482939-A | ANTI-PLATELET ACTIVATING FACTOR ACTIVITIES | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1996-01-09 | — | — | US | disclosed |
| US-5389633-A | ANTIASTHMATIC AGENTS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1995-02-14 | — | — | US | disclosed |
| EP-0562439-A1 | Triazolopyridazines as antioasthmatics | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1993-09-29 | — | — | EP | disclosed |
| US-4826834-A | BACTERICIDES | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1989-05-02 | — | — | US | disclosed |
| EP-0229369-A2 | Cephalosporins, process for their preparation and pharmaceutical compositions containing them | Takeda Chemical Industries, Ltd. (JP) | 1987-07-22 | — | — | EP | disclosed |
| EP-0216385-A2 | Antibacterial compounds | Takeda Chemical Industries, Ltd. (JP) | 1987-04-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230039553-A1 | CD73 COMPOUNDS | ENTPD5, ENTPD1, NT5E | KDM4E 944/4885ALDH1A1 347/4885SMN1; SMN2 3774/4885 |
| US-12110294-B2 | CD73 compounds | ENTPD5, ENTPD1, NT5E | KDM4E 1125/4885ALDH1A1 138/4885SMN1; SMN2 3453/4885 |
| US-10858335-B2 | 2,3-Disubstituted pyridine compounds as TGF-β inhibitors and methods of use | SMAD3, TGFBR1, TGFBR2 | KDM4E 984/4885ALDH1A1 2008/4885SMN1; SMN2 3883/4885 |
| US-20190284155-A1 | 2,3-Disubstituted Pyridine Compounds as TGF-Beta Inhibitors and Methods of Use | TGFBR2, ACVR1, TGFBR1 | KDM4E 1322/4885ALDH1A1 1958/4885SMN1; SMN2 3803/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.